Haley Haught
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$638
- AstraZeneca$504
- Bayer$498
- Novo Nordisk$436
- Novartis$430
- Lilly USA, LLC$389
- plus $3K from 26 others
What the payments were for
- Food & beverage$5,449100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 37 | $638 |
| AstraZeneca | 19 | $504 |
| Bayer | 28 | $498 |
| Novo Nordisk | 27 | $436 |
| Novartis | 27 | $430 |
| Lilly USA, LLC | 24 | $389 |
| GSK | 19 | $340 |
| AbbVie | 16 | $257 |
| Eisai Inc. | 12 | $244 |
| Merck | 15 | $232 |
| Boehringer Ingelheim | 12 | $197 |
| Otsuka America Pharmaceutical, Inc. | 8 | $190 |
| Alkermes, Inc. | 7 | $189 |
| Astellas Pharma US Inc | 7 | $115 |
| Phathom Pharmaceuticals, Inc. | 7 | $103 |
| Pfizer | 6 | $102 |
| Exact Sciences | 6 | $90 |
| Amarin Pharma, Inc. | 5 | $86 |
| Lundbeck LLC | 5 | $80 |
| Esperion Therapeutics, Inc. | 5 | $69 |
| Abbott | 3 | $43 |
| Ardelyx, Inc. | 2 | $34 |
| Biogen | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Organon | 1 | $17 |
| Indivior Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$5,449 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $36,699 |
| KerendiaFinerenone | 24 | $28,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $26,628 |
| TrulicityDulaglutide | 18 | $26,614 |
| LinzessLinaclotide | 38 | $24,338 |
| FarxigaDapagliflozin Propanediol | 24 | $19,385 |
| EliquisApixaban | 16 | $18,487 |
| RybelsusSemaglutide | 17 | $16,243 |
| MounjaroTirzepatide | 13 | $15,507 |
| TradjentaLinagliptin | 17 | $14,510 |
| JanuviaSitagliptin Phosphate | 16 | $13,874 |
| XareltoRivaroxaban | 17 | $13,252 |
| VascepaIcosapent Ethyl | 25 | $10,305 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $6,493 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $436 | $52,94245 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $389 | $42,12131 claims |
| BayerKerendia | $498 | $28,25724 claims |
| GSKTrelegy Ellipta | $340 | $26,62820 claims |
| AbbVieLinzess | $257 | $24,33838 claims |
| AstraZenecaFarxiga | $504 | $19,38524 claims |
| PfizerEliquis | $102 | $18,48716 claims |
| Boehringer IngelheimTradjenta | $197 | $14,51017 claims |
| MerckJanuvia | $232 | $13,87416 claims |
| Johnson & JohnsonXarelto | $23 | $13,25217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Delhi
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.